Robert F. Kennedy Jr. is attempting to loosen federal restrictions on peptide drugs as he pushes to expand access to substances that have largely been kept off the market due to a lack of safety data. The U.S. Department of Health and Human Services, under his leadership, recently voted to overturn a ban that prevented compounding pharmacies from manufacturing these unapproved drugs. This move marks a significant shift in how the government regulates biological compounds that have not undergone the standard clinical testing required for approval.
Stacking the Board
While Kennedy has previously stated that independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence, the process leading to the vote suggests a different reality. Earlier this year, Kennedy announced his intention to reverse the ban on manufacturing. Beth Mole, writing for Ars Technica, noted at the time that watchdogs suspected Kennedy would work to stack the advisory board with allies who had predetermined interests in the sale of these unapproved peptides.
That suspicion proved accurate. In June, Kennedy added several new members to the advisory group. With one exception, these newly appointed members had obvious conflicts of interest, such as direct involvement in the manufacture or sale of the very peptides under review. When the group convened, the new members provided the decisive votes to overturn the ban, while the original members all voted against the decision.
It is a pattern that repeats itself in regulatory battles across various sectors. When a political appointee replaces career scientists with individuals who have a financial stake in the outcome, the integrity of the process often collapses. The resulting policy shift rarely reflects a genuine scientific consensus, but rather the interests of the newly empowered stakeholders.
Testing the Limits
During the meeting, a committee member asked an FDA official whether the agency had ever approved a substance that had never been tested in humans before. The official responded that it had not. That fact highlights a significant gap between the agency’s standard operating procedures and the decision being made by the advisory board.
Related: Nurse Finds Art on Every City Visit
Despite the lack of rigorous testing, the advisory panel recommended removing the restriction on compounding pharmacies. The committee’s role is advisory, and the FDA is not bound to follow its suggestions. However, if the agency does reject the recommendation, it risks placing its own experts in direct conflict with the administration’s wishes. Since Kennedy can simply fire those experts, the pressure to align with his preferences is immense.
Medical professionals and patient advocates have raised alarms about the potential health risks associated with these unapproved formulations. Without the thorough vetting required for FDA approval, patients could be exposed to substances with unknown side effects or dangerous interactions. The transition from a tightly regulated market to one with looser oversight could lead to widespread misuse of potent biological agents.
Industry insiders suggest that the decision may also open the door to widespread patent abuse. By removing restrictions, the administration could inadvertently facilitate a race to market for companies seeking to capitalize on the demand for these compounds. This dynamic often leads to a flood of similar products, many of which may be of dubious quality or origin.
For those interested in the broader implications of regulatory shifts, similar debates regarding access to specialized treatments are ongoing in other areas of healthcare. [1]Nurse Finds Art on Every City Visit explores how individuals handle complex medical settings, illustrating the challenges many face when seeking care outside of standard channels.